

Communication Address:

Solara Active Pharma Sciences Limited

2nd Floor, Admin Block 27, Vandaloor Kelambakkam Road, Keelakottaiyur Village, Melakottaiyur (Post)

Chennai – 600 127, India Tel : +91 44 43446700 Fax : +91 44 47406190

E-mail: investors@solara.co.in

www.solara.co.in

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex

June 19, 2024

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai – 400 001

Bandra (E), Mumbai – 400 051

Scrip Code: 541540 Scrip Code: SOLARA

Dear Sir/Madam,

Subject: Allotment of 1,19,98,755 partly paid-up equity shares of Solara Active Pharma Sciences Limited ("Company") of face value of ₹ 10 each ("Equity Shares") – Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI Listing Regulations")

This is with reference to our intimation on the outcome of the meeting of the board of directors of the Company ("Board") dated July 5, 2023, wherein the Board approved the raising of funds through rights issue and our intimation on the outcome of the meeting of the Rights Issue Committee dated May 9, 2024, approving the various terms of the Rights Issue and the Letter of Offer ("Letter of Offer").

In relation to the aforesaid Rights Issue and the Letter of Offer and pursuant to the finalisation of the basis of allotment of the Rights Issue, in consultation with the BSE Limited, designated stock exchange; Choice Capital Advisors Private Limited, Lead Managers; Cameo Corporate Services Limited, Registrar to the Rights Issue; the Rights Issue Committee of the Board of Directors of the Company, at its meeting held today, i.e. June 19, 2024, inter alia, considered and approved the allotment of 1,19,98,755 partly paid up Equity Shares at a price of ₹ 375 per Rights Equity Share (including a premium of ₹ 365 per Rights Equity Share) wherein the applicants were required to pay ₹131.25 per Equity Share on application (face value of ₹ 3.50 per Rights Equity Share and premium of ₹ 127.75 per Rights Equity Share).

Consequent to the said Allotment, the paid-up equity share capital of the Company has increased from  $\ 36,00,52,670$  divided into 3,60,05,267 fully paid up Equity Shares of face value of  $\ 10$  each to  $\ 40,20,48,313$  divided into 3,60,05,267 fully paid up Equity Shares of face value of  $\ 10$  each and 1,19,98,755 partly paid up Equity Shares having face value of  $\ 10$  each (where the Applicants were required to pay face value of  $\ 3.50$  per Rights Equity Share on Application and the balance face value of  $\ 50.50$  on subsequent call(s)).

The aforesaid information is also being hosted on the website of the Company at <a href="https://solara.co.in/investor-relations/rights-issue">https://solara.co.in/investor-relations/rights-issue</a>

The meeting commenced at 10.00 a.m. and concluded at 11.10 a.m.

You are requested to kindly take the above information on record.

Thanking you, Yours faithfully, For Solara Active Pharma Sciences Limited

S. Murali Krishna Company Secretary